ls174t human colon carcinoma cell line (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
97
Structured Review
ATCC
ls174t human colon carcinoma cell line
Ls174t Human Colon Carcinoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1969 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ls174t+human+colon+carcinoma+cell+line/LS+174T/pmc13008539-160-19-27
Average 97 stars, based on 1969 article reviews
Ls174t Human Colon Carcinoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1969 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ls174t+human+colon+carcinoma+cell+line/LS+174T/pmc13008539-160-19-27
Average 97 stars, based on 1969 article reviews
ls174t human colon carcinoma cell line - by Bioz Stars,
2026-09
97/100 stars
Images
Related Articles
other:Article Title: Evaluation of in vitro cytotoxicity and induction potential of açaí ( Euterpe oleracea) extracts in human hepatocytes Article Snippet: Due to limitations, one restriction in funding and second, high cost of the primary hepatocyte-based assays, we utilized the Article Title: Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug. Article Snippet: The antibody−drug conjugate (ADC), IMMU130, of the moderately cytotoxic topoisomerase I inhibitor, SN-38, and the CEACAM5-targeted humanized antibody (mAb), labetuzumab, was evaluated in model systems of human colon carcinoma and in phase I clinical trials of heavily pretreated patients with metastatic colorectal cancer.. The conjugate, designed with a near-homogeneous drug substitution of 7−8 SN-38/mAb and with a linker that released 50% of the drug in ∼20 h, showed significant antitumor effects compared to a nontargeted ADC in human tumor xenografts, which could be augmented in combination with bevacizumab.. The advantage of fractionated dosing was demonstrated, with potential implications for the clinical dosing schedule. In Vitro:Article Title: Perspective: Recommendations for benchmarking pre-clinical studies of nanomedicines Article Snippet: .. The LS174T human colon carcinoma cell line is purchased from the Article Title: Perspective: Recommendations for benchmarking pre-clinical studies of nanomedicines Article Snippet: .. Tumor cell line The LS174T human colon carcinoma cell line is purchased from the Article Title: Recommendations for Benchmarking Preclinical Studies of Nanomedicines Article Snippet: .. The LS174T human colon carcinoma cell line is purchased from the |